Gender differences in response to antipsychotic treatment in outpatients with schizophrenia

Psychiatry Research

Volumn 153, Issue 3, 2007, Pages 225-231

  Usall, Judith ^a   Suarez, David ^a   Haro, Josep Maria ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antipsychotic response; Gender differences; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; FEMALE; HEALTH STATUS; HUMANS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; TREATMENT OUTCOME;

EID: 35449005330     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2006.09.016     Document Type: Article

References (23)

1. Benson K., and Hartz A.J. A comparison of observational studies and randomized, controlled trials. New England Journal of Medicine 34 (2000) 1878-1886
2. Ciapparelli A., Ducci F., Carmassi C., Carlini M., Paggini R., Catena M., Bottai M., and Dell'Osso M. Predictors of response in a sample of treatment-resistant psychotic patients on clozapine. European Archives of Psychiatry and Clinical Neuroscience 254 (2004) 343-346
3. Di Paolo T. Modulation of brain dopamine transmission by gender steroids. Annual Review of Neuroscience 5 1 (1994) 27-42
4. Goldstein J.M., Cohen L.S., Horton N.J., Lee H., Andersen S., Tohen M., Crawford A., and Tollefson G. Gender differences in clinical response to olanzapine compared with haloperidol. Psychiatry Research 110 1 (2002) 27-37
5. Guy G. Clinical global impression. ECDEU Assessment Manual for Psychopharmacology, Revised (1976), National Institute of Mental Health, Rockville, MD
6. Hafner H., Behrens S., De Vry J., and Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for gender differences in schizophrenia. Psychiatry Research 38 (1991) 125-134
7. Haro J.M., Edgell E.T., Frewer P., Alonso J., Jones P.B., and on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatrica Scandinavica 107 Suppl 416 (2003) 1-9
8. Haro J.M., Edgell E.T., Jones P.B., Alonso J., Gavart S., Gregor K.J., Wright P., Knapp M., and SOHO Study Group. The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods and recruitment. Acta Psychiatrica Scandinavica 107 (2003) 222-232
9. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodríguez M.J., Rele R., Orta J., Kharveng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., Jones P.B., and SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica 107 Suppl 416 (2003) 16-23
10. Labelle A., Light M., and Dunbar F. Risperidone treatment of outpatients with schizophrenia: no evidence of gender differences in treatment response. Canadian Journal of Psychiatry 46 6 (2001) 534-541
11. Leung A., and Chue P. Gender differences in schizophrenia, a review of the literature. Acta Psychiatrica Scandinavica 101 (2000) 3-38
12. Lieberman J.A., Safferman A.Z., Pollack S., Szymanski S., Johns C., Howard A., Kronig M., Bookstein P., and Kane J.M. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry 151 (1994) 1744-1752
13. Perry P.J., Miller D.D., Arnott S.V., and Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. American Journal of Psychiatry 148 (1991) 231-235
14. Pinals D.A., Malhotra A.K., Missar C.D., Picar D., and Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophrenia Research 22 3 (1996) 215-222
15. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff B., Bilder R., Goldman R., and Lieberman J.A. Predictors of treatment response from a first-episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 156 4 (1999) 544-549
16. Schatzberg A.F., Cole J.O., and DeBattista Ch. Manual of Clinical Psychopharmacology (2005), American Psychiatric Press, Washington, DC
17. Seeman M.V. Neuroleptic prescriptions for men and women. Social Pharmacology 3 (1989) 219-236
18. Seeman M.V. The role of estrogen in schizophrenia. Journal of Psychiatry & Neuroscience 21 (1996) 123-127
19. Shtasel D.L., Gur R.E., Gallacher F., Heimberg C., and Gur R.C. Gender differences in the clinical expression of schizophrenia. Schizophrenia Research 7 (1992) 225-231
20. Szymanski S., Lieberman J.A., Alvir J.M., Mayerhoff D., Loebel A., Geisler S., Chakos M., Koreen A., Jody D., Kane J., Woerner M., and Cooper T. Gender differences in onset of illness, treatment response, course and biological indexes in first episode schizophrenic patients. American Journal of Psychiatry 152 (1995) 698-703
21. Szymanski S., Lieberman J.A., Pollack S., Kane J.M., Safferman A.Z., Munne R., Umbricht D., Woerner M., Masiar S., and Kronig M. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biological Psychiatry 39 (1996) 249-254
22. Usall J., Ochoa S., Araya S., Gost A., Busquets E., and Grupo NEDES. Sintomatología y género en la esquizofrenia. Actas Españolas de Psiquiatría 28 4 (2000) 219-223
23. Williams A. EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-208